POEMS syndrome, calciphylaxis and focal segmental glomerulosclerosis – VEGF as a possible link

Dorothee Heck1*, Miriam Mergen2, Athina Ganner2, Jaroslav Pelisek3, Irina Mader4, Cornelius Weiller1 and Wolf-Dirk Niesen1

Abstract

Background: Polyneuropathy organomegaly endocrinopathy M-protein skin changes (POEMS) syndrome is a rare cause of polyneuropathy. Calciphylaxis, a severe disease leading to necrotic ulcers of the skin, is associated with POEMS syndrome and also with renal disease. This case report describes a patient with POEMS syndrome plus primary focal segmental glomerulosclerosis.

Case presentation: A 27-year-old Caucasian woman with chronic renal insufficiency due to focal segmental glomerulosclerosis and calciphylaxis presented to our institution with polyneuropathy and encephalopathy. An extensive diagnostic workup revealed POEMS syndrome. Serum concentrations of vascular endothelial growth factor (VEGF) were highly elevated, consistent with POEMS syndrome.

Conclusion: To our knowledge, this is the first report of a patient with POEMS syndrome and primary focal segmental glomerulosclerosis. The combination of POEMS syndrome, calciphylaxis and primary focal segmental glomerulosclerosis may be coincidental, suggesting the need for additional studies to confirm or exclude this association. VEGF may be an important pathogenetic link, suggesting that treatment with antiangiogenic agents may improve patient outcomes.

Keywords: POEMS syndrome, Calciphylaxis, Focal segmental glomerulosclerosis, VEGF, Strio-pallido-dentate calcinosis

Background

POEMS (polyneuropathy, organomegaly, endocrinopat-hy, M-protein, skin changes) syndrome is a rare multisystem disease caused by a monoclonal gammopathy. POEMS syndrome might be a risk factor for calciphylaxis by upregulating vascular endothelial growth factor (VEGF) and proinflammatory cytokines [1]. Calciphylaxis is characterized by calcification of the arterioles, resulting in rapidly progressive necrotic ulcers of the skin and subcutis. Calciphylaxis is frequently associated with renal failure. One-year mortality rates are high, with death mostly due to sepsis. This report describes a patient with the combination of POEMS syndrome, calciphylaxis and primary focal segmental glomerulosclerosis (FSGS) and discusses a possible pathogenetic link.

Case presentation

A 27-year-old Caucasian woman recently diagnosed with chronic renal failure, pulmonary embolism and calciphylaxis was admitted to our hospital due to weakness and mental alterations. Two months earlier, this patient had presented with a severe nephrotic syndrome, with a renal biopsy revealing a primary FSGS with typical almost complete podocyte foot process fusion on electron microscopy. Calciphylactic skin changes were confirmed by deep skin biopsies, which showed calcifying panniculitis. The patient was started on daily hemodialysis to treat her calciphylaxis and owing to a poor response of FSGS to steroids. She was also administered sodium thiosulfate thrice weekly, along with careful wound care and lymphatic drainage.

* Correspondence: dorothee.heck@uniklinik-freiburg.de
1Department of Neurology and Clinical Neurophysiology, University Hospital Freiburg, Freiburg, Germany
Full list of author information is available at the end of the article

© 2014 Heck et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Physical examination showed obesity, sclerotic lipolymphedema, deep necrotic ulcers on the lower legs and generalized pitting edema (Figure 1). Peripheral pulses were intact. Neurological examination revealed clouding of consciousness and psychomotor slowing. Inspection of her hands showed noticeable atrophy of the interosseal and thenar muscles. She was able to hold her arms over her head but could not lift her legs due to pain and weakness. The reflexes of her upper extremities were symmetrically normal. Owing to hyperalgesia of the limbs, however, she did not tolerate a knee jerk. An ophthalmologic examination showed physiological findings.

Electrophysiological testing, including nerve conduction tests and an electromyogram, revealed an axonal-demyelinating polyneuropathy. Electroencephalography showed a mild encephalopathy, but no epileptiform activity.

Magnetic resonance imaging (MRI) of the brain showed fine calcifications of the basal ganglia and the dentate nuclei, indicating strio-pallido-dentate calcnosis. Bilateral chronic lesions in the putamen and in the head of the caudate nucleus were also observed. There was no evidence of mitochondrial encephalopathy, because lactate was not detectable on magnetic resonance spectroscopy (Figure 2).

Laboratory results (Table 1) showed anemia and leukocytosis. C-reactive protein concentration was highly elevated. There was marked hypoalbuminemia and nephrotic-range proteinuria, with a urinary protein/creatinine ratio of 19.9 g/g. Creatinine kinase activity was normal, but thyroid function tests revealed hypothyroidism. The patient experienced one episode of hypoglycemia of 50 mg/dL. Secondary hyperparathyroidism was detected, consistent with chronic renal insufficiency. Serum immunofixation revealed a monoclonal gammopathy (immunoglobulin G lambda). Serum VEGF levels were highly significantly elevated (1.329 ± 80 pg/mL). Extensive immunologic testing was unremarkable. The cerebrospinal fluid showed a mild blood–brain barrier disruption.

Histological and cytological examination of the bone marrow showed a proliferation of plasma cells, consistent with a monoclonal gammopathy of undetermined significance (MGUS). Additional histological examinations of the renal biopsy did not provide any evidence for renal involvement in MGUS. Muscle biopsy revealed type II fiber atrophy. There was no evidence of muscular inflammation, metabolic myopathy or a mitochondrial disorder.

POEMS syndrome was diagnosed based on polyneuropathy, monoclonal plasma cell disorder with IgG lambda, elevated serum VEGF, extravascular volume overload, endocrinopathy and skin changes, consistent with proposed diagnostic criteria [2].

The patient was treated with cyclophosphamide, dexamethasone, rituximab and bortezomib. Calciphylactic skin changes and hyperalgesia ameliorated gradually. Neurocognitive abilities improved slightly and mobilization was possible with the aid of a walker, but the patient still requires care.

Conclusions
Neurological manifestations in calciphylaxis are rare, but could explain myopathy and encephalopathy in our patient.
Ischemic myopathy in calciphylaxis is associated with proximal muscle weakness and elevated creatinine kinase activity. Muscle biopsy usually shows calcium deposits in vessel walls and muscle atrophy [3]. Similarly, our patient had type II fiber atrophy on muscle biopsy and polyphasic action potentials on EMG. However, her normal creatinine kinase activity argues against an active myopathy in our patient.

Additionally, calciphylaxis may have been etiologic for the encephalopathy and strio-pallido-dentate calcinosis in our patient. Neuropsychiatric diseases are a typical clinical presentation in patients with strio-pallido-dentate calcinosis, which is most frequently caused by disorders of calcium metabolism in adults [4]. Calcification of the basal ganglia in calciphylaxis has only been reported once on autopsy. Interestingly, this patient also had FSGS [3].

To our knowledge, this is the first report of a patient with POEMS syndrome, calciphylaxis and primary FSGS.

| Variable                        | Value (normal range) |
|---------------------------------|----------------------|
| Hemoglobin, g/dL                | 7.1 (12–18)          |
| White blood cell count, × 10^3/μL | 15.99 (4.3–10)       |
| Platelet count, × 10^3/μL       | 347 (140–400)        |
| C-reactive protein, mg/dL       | 100 (<5)             |
| Albumin, g/dL                   | 0.9 (3.5–5.2)        |
| Creatinine, serum (SCr), mg/dL  | 1.78 (0.51–0.95)     |
| Urea nitrogen, serum (SUN), mg/dL | 28 (12.8–42.8)      |
| Creatinine kinase activity, U/L | 51 (<170)            |
| Bilirubin, mg/dL                | <0.08 (<0.9)         |
| GOT, U/L                        | 20 (10–35)           |
| Calcium, mmol/L                 | 1.9 (2.15–2.5)       |
| Ionized calcium, mmol/L         | 1.22 (1.15–1.29)     |
| Phosphate, mmol/L               | 1.6 (0.81–1.45)      |
| INR                             | 1.14 (0.85–1.15)     |
| PTT, s                          | 55 (25.9–36.6)       |
| Protein C functional, %         | 73 (70–134)          |
| Protein S functional, %         | 73 (60–130)          |
| Lupus anticoagulant             | 1.04 (1.09–1.34)     |
| Immunofixation                  | Monoclonal gammopathy IgG-lambda |
| PTH, pg/mL                      | 78 (15–65)           |
| TSH, μU/mL                      | 9.47 (0.27–4.20)     |
| T3, pmol/L                      | 2.04 (3.4–6.8)       |
| T4, pmol/L                      | 14.4 (10.6–22.7)     |
| Glucose, mg/dL                  | Minimum 50 (60–140 mg/dL) |
| Insulin, pmol/L                 | 20 (18–173)          |
| Vitamin D, ng/mL                | <3.00 (20–70)        |
| VEGF, pg/mL                     | 1.329 ± 80 (382 ± 212) |
| CH50, E/mL                      | 36 (20–50)           |
| C3, g/L                         | 0.91 (0.90–1.80)     |
| C4, g/L                         | 0.62 (0.10–0.40)     |
| C3d, mg/L                       | 7.8 (<9)             |
| Rheumatoid factor, IE/mL        | <10 (<16)            |
| Antinuclear antibodies          | negative (negative)  |
| ANCA                            | negative (negative)  |
| Cryoglobulins                   | negative (negative)  |
| Phospholipid antibodies, U/mL   | 1 (<14)              |
| Protein/creatinine (urine), g/g | 19.9 (<0.15)         |
| Cerebrospinal fluid protein, mg/L | 112 (<450)          |
| Cerebrospinal fluid cell count, U/μL | 3 (<5)              |
| Cerebrospinal fluid lactate, mmol/L | 1.29 (1.5–2.1) |

Note: Conversion factors for units: Bilirubin in mg/dL to μmol/L × 17.1; SCr in mg/dL to μmol/L, × 88.4; SUN in mg/dL to mmol/L, × 0.357; Glucose in mg/dL to mmol/L, × 0.05551; Vitamin D in ng/mL to nmol/L, × 2.496.
Several case reports have proposed an association between calciphylaxis and POEMS syndrome [1,5,6], and calciphylaxis has been described in patients with FSGS [3,7]. Moreover, FSGS is related to multiple myeloma and treatment of the underlying plasma cell proliferative disorder improved FSGS, although POEMS syndrome was not mentioned in that report [8]. Nephrotic syndrome, typical of primary FSGS, was not observed in 52 Japanese patients with POEMS syndrome and renal pathology [9]. Serial renal biopsies of a patient with POEMS syndrome and recurrent acute renal failure initially showed thrombotic microangiopathy-like lesions, followed sequentially by membranoproliferative-like features and glomerulosclerosis [10]. Consistent with secondary FSGS, glomerulosclerosis developed after preceding renal injury, when proteinuria was mild. Our patient had features typical of primary FSGS, including nephrotic range proteinuria and renal biopsy findings with an almost complete podocyte foot process fusion on electron microscopy. To our knowledge, this is the first report of a patient with both POEMS syndrome and primary FSGS.

VEGF may constitute a common pathogenetic link among POEMS syndrome, calciphylaxis and primary FSGS. Elevated serum VEGF levels are one of the major criteria for the diagnosis of POEMS syndrome [2]. VEGF is essential for both physiological and pathological angiogenesis and is induced by hypoxia [11]. Proliferating endothelial cells and plasma cells produce VEGF [12]. In the kidney, VEGF is secreted by podocytes and is crucial for the maintenance of the glomerular endothelium [13]. The tyrosine kinase VEGFR-2 is regarded as the main receptor for VEGF. VEGFR-2 can be blocked by the tyrosine kinase VEGFR-2 is regarded as the main receptor for VEGF. VEGFR-2 can be blocked by the tyrosine kinase inhibitor sunitinib, delaying tumor angiogenesis. Plasma VEGF concentrations may be elevated in patients treated with sunitinib [14]. Immunohistochemical staining of a renal biopsy specimen from a patient developing FSGS under treatment with sunitinib revealed that VEGF was markedly positive in his podocytes and renal dysfunc tion was dose-dependent [15]. Moreover, children with primary nephrotic syndrome had higher plasma VEGF levels during the active nephrotic phase than during remission [16]. Thus, VEGF has been indirectly implicated in the pathology of FSGS, as well as to promote calcification, together with bone morphogenetic proteins, in vascular smooth muscle cells. Thus, VEGF may contribute to the development of calciphylaxis [1].

To conclude, we report the first case of a patient with POEMS syndrome, calciphylaxis and primary FSGS. Because the association of these three conditions may be coincidental, further studies are needed to prove this association. VEGF may be a common pathogenetic factor, suggesting that treatment with antiangiogenic agents may improve patient outcomes.

Consent
Written informed consent was obtained from the guardian of our patient for publication of this case report and the accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Abbreviations
POEMS syndrome: Polyneuropathy organomegaly endocrinopathy M-protein skin changes syndrome; FSGS: Focal segmental glomerulosclerosis; VEGF: Vascular endothelial growth factor.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
DH analyzed the case and wrote the manuscript. MM and DH treated the patient. AG and WDN supervised patient treatment. JP measured and interpreted serum VEGF concentrations. IM performed imaging analyses. All authors made substantial contributions to the interpretation of the case and read and approved the final manuscript.

Acknowledgements
We thank Dr Bernd Jänigen and his team from the Department of Surgery, University Hospital Freiburg, Germany, for providing images of the calciphylaxis-induced skin changes. The article processing charge was funded by the German Research Foundation (DFG) and the Albert Ludwigs University Freiburg in the funding programme for Open Access Publishing.

Received: 24 June 2014 Accepted: 18 October 2014
Published online: 05 November 2014

References
1. Hineno A, Kinoshita T, Kinoshita M, Arakura F, Naito KS, Shimojima Y, Matsuda M, Yoshida K, Ikeda SI: Calciphylaxis as a catastrophic complication in a patient with POEMS syndrome. Case Rep Neurol 2009, 1(1):47–53.
2. Dispensieri A: POEMS syndrome: 2014 Update on diagnosis, risk stratification, and management. Am J Hematol 2014, 89(2):213–223.
3. Flanigan KM, Bromberg MB, Gregory M, Baringer JR, Jones CR, Nester TA, Klatt EC, Townsend JJ: Calciphylaxis mimicking dermatomyositis: ischemic myopathy complicating renal failure. Neurology 1998, 51(8):1634–1640.
4. Bonazza S, La Morgia C, Martinelli P, Capellari S: Strio-pallido-dentate calcinosis: a diagnostic approach in adult patients. Neurol Sci 2011, 32(4):537–545.
5. Lee FY, Chiu HC: POEMS syndrome with calciphylaxis: a case report. Acta Derm Venereol 2011, 91(1):96–97.
6. Novoa RA, Honda KS, Campagnaro E, Genstenblith MR: Hypertensive emergency, mastlike telangiectasia, and calciphylaxis in POEMS syndrome. JAMA Dermatol 2014, 150(6):667–669.
7. Budisavljevic MN, Cheek D, Ploth DW: Calciphylaxis mimicking dermatomyositis: ischemic myopathy complicating renal failure. J Am Soc Nephrol 1996, 7(1):978–982.
8. Dingli D, Larson DR, Plevak MF, Grande JP, Kyle RA: Focal and segmental glomerulosclerosis and plasma cell proliferative disorders. Am J Kidney Dis 2005, 46(3):278–283.
9. Nakamoto Y, Inai H, Yasuda T, Waku H, Miura AB: A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome. Nephrol Dial Transplant 1999, 14(10):2370–2378.
10. Higashi AY, Nogaki F, Kato J, Ono T, Fukatsu A: Serial renal biopsy findings in a case of POEMS syndrome with recurrent acute renal failure. Clin Exp Nephrol 2012, 16(1):173–179.
11. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20(21):4368–4380.

12. Bellamy WT: Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol 2001, 28(6):551–559.

13. Schrijvers BF, Flyvbjerg A, De Vriese AS: The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004, 65(6):2003–2017.

14. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24(1):16–24.

15. Takahashi D, Nagahama K, Tsuura Y, Tanaka H, Tamura T: Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction. Clin Exp Nephrol 2012, 16(2):310–315.

16. Cheong HI, Lee JH, Hahn H, Park HW, Ha IS, Choi Y: Circulating VEGF and TGF-beta1 in children with idiopathic nephrotic syndrome. J Nephrol 2001, 14(4):263–269.

Cite this article as: Heck et al.: POEMS syndrome, calciphylaxis and focal segmental glomerulosclerosis – VEGF as a possible link. BMC Neurology 2014 14:210.

doi:10.1186/s12883-014-0210-3

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit